Meronem

Meropenem, the active ingredient in Meronem, is a carbapenem antibiotic presented as a powder for injection for intravenous use. It treats a range of serious bacterial infections, including intra‑abdominal, urinary tract, respiratory, bloodstream and central nervous system infections, in hospitalized patients requiring parenteral therapy. The drug is supplied in a sterile lyophilized form that is reconstituted before infusion.

GNH USA supplies Meronem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used to treat severe infections caused by Gram‑negative and Gram‑positive bacteria.

- Complicated intra‑abdominal infections: achieves clinical cure and bacterial eradication in patients with polymicrobial peritonitis. - Complicated urinary tract infections: provides effective bacterial clearance in cases resistant to other agents. - Nosocomial pneumonia: improves outcomes in ventilator‑associated and hospital‑acquired pneumonia. - Septicemia: rapidly reduces bacteremia and supports hemodynamic recovery. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis.

Adverse reactions to Meropenem vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis following infusion. - Diarrhea: loose stools, may be self‑limiting. - Infusion site reactions: erythema or pain at the injection site. - Elevated liver enzymes: transient increase in ALT/AST. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Seizures: risk increased in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: potential for severe intestinal infection. - Thrombocytopenia: marked reduction in platelet count. - Renal toxicity: acute kidney injury in susceptible individuals. - Severe neutropenia: marked decrease in neutrophil count.

When using Meropenem, clinicians should consider several precautionary measures to ensure safe therapy. - Renal impairment: adjust dose according to creatinine clearance. - History of seizures: monitor for neurotoxicity and consider alternative agents. - Pregnancy Category B: use only when the potential benefit justifies the potential risk to the fetus. - Allergy to β‑lactams: assess cross‑reactivity before initiating therapy. - Concurrent valproic acid therapy: avoid due to increased risk of seizures. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: concomitant use can lower valproate levels and increase seizure risk. - Nephrotoxic agents (e.g., aminoglycosides): combined high doses may exacerbate renal injury.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - Warfarin: observe INR values for potential anticoagulation changes. - Oral contraceptives: efficacy may be reduced; advise alternative contraception. - Other antibiotics: assess for antagonistic effects when used together.